Literature DB >> 848940

Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine.

M Pfeffer, A Jackson, J Ximenes, J P de Menezes.   

Abstract

At equivalent oral doses, cefadroxil has a longer serum half-life, slower urinary excretion rate, greater area under the serum level versus time curve than cephalexin or cephradine, and peak serum concentrations that are 75 to 80% those of cephalexin. The calculated, apparent in vivo volume of distribution of cefadroxil is greater than that of cephalexin. These properties infer greater persistence of cefadroxil in serum and urine and more prolonged in vivo bacterial exposure to cefadroxil than to cephalexin or cephradine. Neither cefadroxil nor cephalexin demonstrates drug accumulation on repeated administration. The serum levels achieved by cefadroxil are unaffected by food. The pharmacokinetic properties of cefadroxil are supportive of the development of clinical efficacy data which could indicate that cefadroxil could be administered at 12-h intervals.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 848940      PMCID: PMC351976          DOI: 10.1128/AAC.11.2.331

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

Authors:  J E GRIZZLE
Journal:  Biometrics       Date:  1965-06       Impact factor: 2.571

2.  An overview of the analysis and interpretation of bioavailability studies in man.

Authors:  J G Wagner
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

3.  Cefadroxil, a new broad-spectrum cephalosporin.

Authors:  R E Buck; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

  3 in total
  17 in total

1.  Phase I study of single-dose BMY-28100, a new oral cephalosporin.

Authors:  R H Barbhaiya; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

2.  Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin.

Authors:  A I Hartstein; K E Patrick; S R Jones; M J Miller; R E Bryant
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

3.  Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.

Authors:  A Verghese; D Roberson; J H Kalbfleisch; F Sarubbi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.

Authors:  H Lode; R Stahlmann; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

5.  Species differences in the pharmacokinetics of cefadroxil as determined in wildtype and humanized PepT1 mice.

Authors:  Yongjun Hu; David E Smith
Journal:  Biochem Pharmacol       Date:  2016-03-12       Impact factor: 5.858

6.  Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects.

Authors:  Rui Liu; Audrey May Yi Tang; Yen Ling Tan; Lie Michael George Limenta; Edmund Jon Deoon Lee
Journal:  Eur J Clin Pharmacol       Date:  2008-09-03       Impact factor: 2.953

Review 7.  Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine.

Authors:  B Tanrisever; P J Santella
Journal:  Drugs       Date:  1986       Impact factor: 9.546

8.  Cefadroxil in the treatment of susceptible infections in infants and children.

Authors:  H Puhakka; E Virolainen
Journal:  Drugs       Date:  1986       Impact factor: 9.546

9.  Penetration and concentration of cefadroxil in sputum, lung and pleural fluid.

Authors:  C H Nightingale
Journal:  Drugs       Date:  1986       Impact factor: 9.546

10.  Clinical pharmacology of cefadroxil in infants and children.

Authors:  C M Ginsburg; G H McCracken; J C Clahsen; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.